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Abstract
Early economic modelling has long been recommended to aid research and development (R&D) decisions 
in medical innovation, although they are less frequently published and critically appraised. A review of 30 
innovations by Grutters et al provides an opportunity to evaluate how early models are used in practice. The 
evidence of early models can be used to inform two types of decision: to continue development (“stop or go”) or 
to alter future R&D activities. I argue that early models have limited use in stop or go decisions, as less resource 
and data undermine the reliability of the models’ indicative estimates of cost-effectiveness. Whilst they are far 
more useful for informing future R&D directions, the best techniques available from statistical decision science, 
such as value of information analysis, are not regularly used. It is highly recommended that early models adopt 
these methods to best deal with uncertainty, quantify the potential value of further research, identify areas of 
study with the greatest potential benefit and generate recommendations on study design and sample size.
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Introduction
The development of innovative healthcare products such 
as pharmaceuticals and medical devices is highly resource 
intensive, involving billions of dollars.1 Public purchasers are 
the most common procurers of these products, with more 
than half of global health expenditure publicly funded.2 
Manufacturers therefore have an obvious interest in trying to 
identify the social value of potential investments as early as 
possible in order to maximize revenue. Early health economic 
modelling is often proposed to aid investment decisions by 
estimating the expected costs and health benefits generated 
by an innovation, compared with current standards of care.
Early modelling has been recommended for at least 20 
years.3,4 However, compared with more typical, later-stage 
decision models that are developed to inform adoption and 
reimbursement decisions (hereafter ‘late-stage models’), the 
details of early models are less frequently published. The 
recent retrospective analysis of 32 early models by Grutters 
and colleagues is therefore a welcome addition to this relatively 
under researched area.5 Their sample covers a variety of 
product development stages and clinical areas, with the vast 
majority commissioned by medical device companies. There 
is explicit focus on the early economic models themselves, 
rather than a broader early health technology assessment 
(HTA) process in which additional factors such as regulatory 
environment and safety profile are deliberated.6 ‘Early’ is 
defined as being any point before healthcare payers are making 
decisions about whether or not to adopt the intervention – the 
traditional point at which decision models are developed. 
Grutters set out to address two questions relating to early 
models: (i) how useful the models were in establishing 
potential cost-effectiveness and (ii) exploring how the results 
affected the subsequent design or implementation of the 
intervention. Another way of framing these questions is 
whether the early model informed decisions about whether 
to (i) continue development (“stop or go”) or (ii) alter future 
research and development (R&D) activities (ie, by focusing 
additional research on promising patient groups). Since the 
principal motivation for decision modelling is to inform 
decisions, I agree that these are the principal justifications 
for developing early models. I argue that early models are far 
better at answering (ii) than (i). 
Stop or Go?
“Potential” cost-effectiveness is a low bar that a vast majority 
of early models clear. Every intervention in Grutters’ sample 
demonstrated some scenario in which it was cost-effective, as 
did an earlier smaller review by Markiewicz and colleagues.7 
This is not surprising. First, compared with late-stage models, 
early models are programmed with less complete data of lower 
quality and higher uncertainty. Being built at an earlier phase 
of product development means that fewer trials will have 
been conducted, fewer patients treated and fewer outcomes 
monitored. Exploratory analyses of cost-effectiveness that 
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accommodate this lack of data such as threshold or headroom 
analysis are therefore required.8 Testing large variations 
in critical drivers of cost-effectiveness, particularly the 
treatment’s cost and effectiveness, mean that the likelihood of 
some combination of parameters producing a cost-effective 
outcome is inherently high. 
Developers of healthcare innovations may even have valid 
reasons for continuing development of products even if early 
models suggest that they will not be cost-effective. Every 
model is designed to address a particular decision problem; 
aspects include the perspective of the analysis (ie, health 
sector, multi-sector or societal), comparator interventions, 
the patient population and the relevant outcome measures. 
A stop recommendation from an early model could reflect 
different decision problems using scenario analysis, but 
for practical and technical reasons it may not be able to 
reproduce scenarios for all potential healthcare markets that 
an innovation has access to. 
Last, early models are generally less well-resourced than 
late-stage models. The incentives for investing more in the 
latter are much stronger as they are a formal requirement in 
many countries’ HTA frameworks and can therefore directly 
influence the profitability of an intervention.9 These resources 
help the model maintain methodological standards set out by 
an agency’s reference case10 when it is subject independent 
critical appraisal in the HTA process. The relative under-
resourcing of early models may lead to suboptimal modelling 
approaches or model structures being adopted, producing less 
reliable estimates of cost-effectiveness. All of Grutters’ early 
models, for instance, use more simplistic cohort Markov and 
decision tree structures. Whilst such approaches can often 
be appropriate,11 more advanced simulation methods may 
be overlooked by early modellers for budgetary reasons even 
when they are the preferred option.
Develop Differently
The case for using early models to inform the direction 
of R&D of an intervention is much stronger. Grutters et al 
highlight several different ways in which their models were 
used for this purpose, such as highlighting the characteristics 
of a diagnostic test that most influenced cost-effectiveness or 
identifying an intervention’s optimal position in the disease 
treatment pathway. 
Decision modelling techniques can also highlight fruitful 
directions for further research – research that investigates 
promising patient subgroups or reduces uncertainty 
around the value of the intervention. Grutters et al limit 
their exploration of uncertainty to deterministic sensitivity 
analysis; analysing the effects of varying the values of one 
or two parameters at a time. Although useful, they fall short 
of the methodological standard of probabilistic sensitivity 
analysis and value of information analysis that are uniformly 
recommended in the literature for early models.4,12–14 These 
analyses investigate the combined parameter uncertainty 
within the model, quantify the potential value of further 
research, identify areas of study with the greatest potential 
benefit and generate recommendations on study design and 
sample size.15,16
The lack of probabilistic analysis is acknowledged by 
Grutters et al and justified on the basis that it “is difficult 
to quantify the (non-statistical) uncertainty… in [terms of 
probability] distributions,” favouring the likes of tornado 
plots when assessing the impacts of the model parameters 
on results. However, deterministic sensitivity analysis and 
tornado plots still require a range of values that each parameter 
is to be varied over. If this range is not specified according 
to uncertainty (ie, through a probability distribution), then 
the influence of that parameter on cost-effectiveness will 
also be a function of a potentially ad hoc range selection. A 
solution to this issue is to estimate parameter values and/or 
probability distributions using structured expert elicitation 
methods, a number of which can be used depending upon the 
type of intervention or parameter under consideration.17 The 
use of structured expert elicitation would not only improve 
the validity of deterministic sensitivity analysis; it will also 
facilitate analytically preferable probabilistic methods and 
value of information analysis. Using these techniques will 
require more resource for early models, however, which may 
not be forthcoming due to the incentive problems noted 
above.
Concluding Remarks
Grutters et al are right to conclude that their early models 
provide insight into the potential cost-effectiveness and 
associated uncertainty of their sample of innovations. 
However, this support comes with several caveats. The 
insights into potential cost-effectiveness are rather limited 
due to the exploratory nature of the analysis and may really 
only be truly useful when development decisions involve 
selecting a limited number of innovations from a portfolio, 
such as in a real options model.18 The insights into the 
drivers of cost-effectiveness and uncertainty, although 
much more worthwhile for R&D decision-making, could 
be greatly enhanced by using the best techniques available 
from statistical decision science. Similar conclusions have 
been reached by Abel et al during a review of early models of 
diagnostics.19
The focus of Grutters and of this article has been on how 
the outputs of early models can be used in R&D decisions. A 
related empirical question that should be the subject of future 
inquiry is whether those outputs should be used. One way of 
approaching this question is to compare the results of an early 
model with those of a late-stage model produced with greater 
resource and populated with better data. Such comparisons 
would be possible using an iterative Bayesian modelling process 
advocated by many in the literature,3,13,14 in which a model is 
regularly updated throughout the product development cycle. 
However, there is little evidence suggesting that this approach 
is being implemented, leaving this validation question around 
early models more challenging to address. Given the scarcity 
of published research on early models, Grutters et al deserve 
credit for at least shedding some light on this frequently 
private and internal process. 
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